These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 12800604)

  • 61. Irinotecan and carboplatin in metastatic or recurrent NSCLC: an update.
    Read W; McLeod H; Govindan R
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):15-7. PubMed ID: 15685828
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The emerging world role of irinotecan in lung cancer.
    Langer CJ
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):15-21. PubMed ID: 11497227
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Paclitaxel/carboplatin as first-line chemotherapy in advanced ovarian cancer: efficacy and adverse effects with special consideration of peripheral neurotoxicity.
    Mayerhofer K; Bodner-Adler B; Bodner K; Leodolter S; Kainz C
    Anticancer Res; 2000; 20(5C):4047-50. PubMed ID: 11268499
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Paclitaxel/carboplatin for the initial treatment of advanced ovarian cancer.
    Neijt JP; du Bois A
    Semin Oncol; 1999 Feb; 26(1 Suppl 2):78-83. PubMed ID: 10190786
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Irinotecan and carboplatin in metastatic or recurrent non-small-cell lung cancer.
    Govindan R; Read W; Faust J; Mc Leod H
    Oncology (Williston Park); 2003 Jul; 17(7 Suppl 7):27-9. PubMed ID: 12886871
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: a Vanderbilt University Cancer Center phase II trial (LUN-46).
    Johnson DH; Paul DM; Hande KR; DeVore R
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):42-6. PubMed ID: 9007120
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Current status of chemotherapy for ovarian cancer.
    Ozols RF
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):61-6. PubMed ID: 7481863
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [A case of papillary adenocarcinoma of the ovary that responded favorably to irinotecan hydrochloride and cisplatin after the administration of paclitaxel and carboplatin].
    Shimoya K; Kunishige I; Okuno Y; Hayashi S; Komura H; Arimoto Y; Otsuki Y
    Gan To Kagaku Ryoho; 2001 Jun; 28(6):845-8. PubMed ID: 11432356
    [TBL] [Abstract][Full Text] [Related]  

  • 69. First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer--a new standard of care?
    du Bois A; Neijt JP; Thigpen JT
    Ann Oncol; 1999; 10 Suppl 1():35-41. PubMed ID: 10219451
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Combination chemotherapy with irinotecan hydrochloride (CPT-11) and mitomycin C in platinum-refractory ovarian cancer.
    Aoki Y; Kurata H; Watanabe M; Fujita K; Tanaka K
    Am J Clin Oncol; 2004 Oct; 27(5):461-4. PubMed ID: 15596911
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Case of pure ovarian squamous cell carcinoma resistant to combination chemotherapy with paclitaxel and carboplatin but responsive to monotherapy with weekly irinotecan.
    Nakamura Y; Kamei T; Shinagawa M; Sakamoto Y; Miwa I
    J Obstet Gynaecol Res; 2015 May; 41(5):809-12. PubMed ID: 25511544
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Complete response to radiation therapy in a patient with chemotherapy-resistant ovarian clear cell adenocarcinoma.
    Takai N; Utsunomiya H; Kawano Y; Nasu K; Narahara H; Miyakawa I
    Arch Gynecol Obstet; 2002 Dec; 267(2):98-100. PubMed ID: 12439556
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Evaluation of the neurotoxicity of paclitaxel and carboplatin by current perception threshold in ovarian cancer patients.
    Doi D; Ota Y; Konishi H; Yoneyama K; Araki T
    J Nippon Med Sch; 2003 Apr; 70(2):129-34. PubMed ID: 12802373
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Outpatient chemotherapy in gynecologic oncology].
    Jobo T
    Gan To Kagaku Ryoho; 2006 Dec; 33 Suppl 2():369-71. PubMed ID: 17469390
    [TBL] [Abstract][Full Text] [Related]  

  • 75. USA update on paclitaxel in ovarian cancer.
    Ozols RF
    Ann Med; 1995 Feb; 27(1):127-30. PubMed ID: 7741991
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Consolidation/maintenance chemotherapy for ovarian cancer.
    Markman M
    Curr Oncol Rep; 2003 Nov; 5(6):454-8. PubMed ID: 14521803
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Synergetic toxicity of DATR, a recombinant soluble human TRAIL mutant, in combination with traditional chemotherapeutics in rats.
    Zou Y; Zhang X; Mao Y; Huang M; Yuan B; Chu Z; Lu G
    Regul Toxicol Pharmacol; 2012 Dec; 64(3):361-6. PubMed ID: 23000416
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Globalization of anti-cancer therapies].
    Akaza H; Aiba K; Isonishi S; Ikeda T; Ohashi Y; Kawai K; Saijo N; Saeki T; Sone S; Tsukagoshi S; Tsuruo T; Boku N; Kato M; Mikami O; Blackledge G; Stribling D
    Gan To Kagaku Ryoho; 2002 Feb; 29(2):205-14. PubMed ID: 11865625
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Identification of candidate SNPs for drug induced toxicity from differentially expressed genes in associated tissues.
    Hasmats J; Kupershmidt I; Rodríguez-Antona C; Su QJ; Khan MS; Jara C; Mielgo X; Lundeberg J; Green H
    Gene; 2012 Sep; 506(1):62-8. PubMed ID: 22759513
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Candidate Gene in Predicting In Vivo Ovarian Cancer Response to Combination Therapy with Paraplatin and Paclitaxel.
    Mirhashemi R; Arena JF; Frudakis T; Lambrou N; Arboleda J; Hunt M; Medranda M; Averette H; Penalver M
    ScientificWorldJournal; 2002; 2():19-20. PubMed ID: 29973784
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.